ARIAD to Present New Preclinical Data on Ponatinib at the American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on ponatinib, the company’s investigational multi-targeted tyrosine kinase inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held April 2-6, 2011 in Orlando, FL.

ARIAD scientist Joseph M. Gozgit, Ph.D., will present the poster entitled, “Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models,” on Tuesday, April 5, 2011 between 8:00 am and 12:00 pm. The ARIAD poster will be presented during the session titled “Experimental and Molecular Therapeutics 25” in Exhibit Hall A4-C, Poster Section 28, Abstract Number 3560.

About ARIAD

ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit www.ariad.com.



CONTACT:

ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208

KEYWORDS:   United States  North America  Florida  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.